Compare Mondaycom Ltd (MNDY) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mondaycom Ltd vs Natera Inc. Common Stock — how do they compare? Mondaycom Ltd trades at $87.78 (market cap $3.57B), while Natera Inc. Common Stock trades at $393.27 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 16× Mondaycom Ltd's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Mondaycom Ltd nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Mondaycom Ltd for 16 Days and Natera Inc. Common Stock for 0 Days on average.
| MNDY | NTRA | |
|---|---|---|
Market Cap | $3.57B | $57.03B |
Volume | 1,023,013 | 1,131,157 |
Sector | Technology | Health |
52-Week High | $205.24 | $425.64 |
52-Week Low | $58.81 | $179.42 |
Typical Hold Time | 16 Days | 0 Days |
Enterprise Value | $2.74B | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Monday.com (MNDY) trades at $84.69, showing minimal daily movement (-0.08%) with neutral technical signals. The company demonstrates strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust revenue growth from $1.23B to $1.4B. Recent news highlights AI integration at Elevate '26 conference and inclusion in multiple growth stock lists, while technical indicators show mixed signals with RSI at neutral levels and key support at $83.
The stock presents a compelling growth story with 61.5% analyst buy ratings and a $108.64 consensus target offering 28% upside. However, elevated valuation multiples (P/E 35.83, EV/EBITDA 50.12) and competitive pressures from Meta's enterprise software push pose risks. Net cash flow turned negative in 2026 (-$737M) despite strong operating performance, requiring monitoring of capital allocation.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Mondaycom Ltd
Monday.com Ltd. is a cloud-based software company providing a Work OS (Operating System) that enables organizations to manage projects, processes, and daily work. The platform is highly customizable, enabling teams to build tailored applications and workflows for a range of use cases, from marketing and sales to software development and HR. monday.com serves clients across numerous industries, aiming to improve transparency, collaboration, and efficiency across the entire enterprise.
Read more on MNDY →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
